TIPS for CEO's
Patent Expiry Status of select drugs
| No. |
Molecule |
Patent Holder | Global Sales (U.S. $) |
Patent Expiry |
| 1 |
Captopril |
BMS |
1091 million |
1995 |
| 2 |
Ranitidine |
Glaxo-Wellcome |
3012 million |
1997 |
| 3 |
Nifedepine |
Bayer |
1290 million |
1997 |
| 4 |
Acyclovir |
Glaxo-Wellcome |
1266 million |
1997 |
| 5 |
Diclofenac |
Novartis |
1158 million |
1999 |
| 6 |
Enalapril |
Merck |
2535 million |
2000 |
back to top
Member CEO's can continue to explore this billion dollar opportunity by clicking here
Visiting CEO's can click here to register and receive the exhaustive list